Scilex Holding Company To Stock GLOPERBA In National Pharmacy Chain Stores
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company announced that its anti-gout medication, GLOPERBA®, will be stocked in leading national pharmacy chains across the U.S. ahead of its expected launch in the first half of 2024. The company is also negotiating with additional chains for stocking arrangements. GLOPERBA®, the first liquid oral colchicine for gout prophylaxis, targets the growing gout treatment market, projected to reach $2.0 billion by 2028. Scilex has increased GLOPERBA® production, with inventory available at Cardinal Health.
February 28, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardinal Health is mentioned as the third-party logistics service provider for Scilex's GLOPERBA®, indicating a role in the distribution process ahead of the 2024 launch.
Cardinal Health's involvement as the logistics service provider for GLOPERBA® underscores its importance in the distribution chain, potentially benefiting from the product's market entry and success. This partnership could enhance Cardinal Health's reputation in pharmaceutical logistics and possibly impact its financial performance positively.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Scilex Holding Company's GLOPERBA® will be stocked in major U.S. pharmacy chains, targeting the growing gout market with a projected value of $2.0 billion by 2028. The company has increased production in anticipation of its 2024 launch.
The announcement of GLOPERBA® being stocked in major pharmacy chains significantly boosts Scilex's market presence and potential revenue streams. The gout treatment market's growth and the unique positioning of GLOPERBA® as the first liquid oral colchicine for gout prophylaxis enhance the product's market potential. Increased production indicates strong company confidence in the product's success.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100